Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 6/20 | 0.59 |
| ▸ | SIRT1 | Q96EB6 | 4/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.37 |
| ▸ | CSF1R | P07333 | 2/20 | 0.37 |
| ▸ | CDC25A | P30304 | 1/20 | 0.37 |
| ▸ | CDC25C | P30307 | 1/20 | 0.37 |
| ▸ | PTGES | O14684 | 1/20 | 0.36 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6513915 | 0.92 | CHEK1 (0.60) | CHEK1SIRT1ADORA1ADORA3CSF1R | |
| SCHEMBL6507557 | 0.88 | CHEK1 (0.62) | CHEK1ADORA3CSF1RCDC25ACDC25C | |
| SCHEMBL6509557 | 0.84 | CHEK1 (0.53) | CHEK1SIRT1ADORA3CSF1RPTGES | |
| SCHEMBL6509924 | 0.84 | CHEK1 (0.70) | CHEK1SIRT1ADORA1ADORA3CSF1R | |
| SCHEMBL6509456 | 0.79 | CHEK1 (0.51) | CHEK1SIRT1ADORA3CSF1RPTGES | |
| SCHEMBL6507672 | 0.77 | CHEK1 (0.60) | CHEK1SIRT1ADORA3CSF1RCDC25A | |
| SCHEMBL6507585 | 0.75 | CHEK1 (1.00) | CHEK1ADORA3CSF1RCDC25ACDC25C | |
| SCHEMBL6510737 | 0.74 | CHEK1 (0.67) | CHEK1CSF1R | |
| SCHEMBL6513239 | 0.69 | CHEK1 (0.53) | CHEK1LMNAHPGD | |
| SCHEMBL6518261 | 0.69 | CHEK1 (0.66) | CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050245563-A1 | Chk-1 inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-11-03 | — | — | US | disclosed |
| WO-2005028474-A2 | PYRAZOLOQUINOLINE DERIVATIVES AS CHK-1 INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245563-A1 | Chk-1 inhibitors | CHKA, CHKB, CHEK1 | CHEK1 3/4885SIRT1 3496/4885ADORA1 4666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.